Healthcare Equipment and Supplies
Company Overview of Lumenis Ltd.
Lumenis Ltd., together with its subsidiaries, develops and commercializes energy-based medical systems for use in minimally invasive procedures worldwide. It operates through three segments: Surgical, Ophthalmic, and Aesthetic. The Surgical segment offers surgical laser systems and accessories used for urology/genitourinary and ENT to hospitals, outpatient clinics, ambulatory surgery centers, and medical practices. The Ophthalmic segment sells ophthalmology laser systems and accessories, such as laser links, slit lamp microscopes, laser indirect ophthalmoscopes, physician eye safety filters, surgical laser probes, and others to ophthalmic practices, outpatient clinics, and ophthalmology depa...
Yokneam Industrial Park
PO Box No. 240
Founded in 1991
Key Executives for Lumenis Ltd.
Lumenis Ltd. does not have any Key Executives recorded.
Lumenis Ltd. Key Developments
Lumenis Showcases its Dual Modality CO2 Laser Solution for Smart Tissue Management Providing Women with Better Options for Gynecology Health Problems
Jun 15 15
Lumenis Ltd. is showcasing its portfolio of CO2 laser solutions for minimally invasive gynecological surgery at the 11th American Association of Gynecologic Laparoscopists (AAGL) International Congress, taking place June 16-19, 2015 in Jerusalem, Israel. The AcuPulse(TM) DUO is the only CO2 laser system that combines free beam and fiber technologies to treat a range of indications in gynecology, including endometriosis, adhesions and uterine fibroids. These gynecological conditions usually affect women during their reproductive years and are associated with pelvic pain and infertility, affecting normal sexual function and quality of life.
Lumenis' broad range of advanced durable and flexible CO2 laser fibers enhance safety by providing a clear visible aiming beam that helps the surgeon target the tissue of interest, and are the only ones with a renewable tip for cost effective and user friendly operation. Along with a designated set of gynecological handpieces, they provide the thermal control and precision required for smart tissue management. Lumenis encourages AAGL attendees to visit booth number 15 to experience the CO2 laser on a specially designated gynecological simulator in order to explore the benefits of the CO2 laser energy.
Lumenis Ltd. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 04:00 PM
May 26 15
Lumenis Ltd. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 04:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Ophir Yakovian, Chief Financial Officer.
Lumenis Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015 ; Provides Earnings Guidance for the Full Year Ending December 31, 2015
May 12 15
Lumenis announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported GAAP net income of $1.6 million or $0.05 per basic and diluted share, compared with the prior-year period's net loss of $3.1 million or $0.10 per basic and diluted share. Non-GAAP net income was $2.3 million or $0.06 per diluted share, versus $2.2 million or $0.07 per diluted share in the same quarter the previous year. Revenue was $68.5 million, up 4.1% from $65.8 million in the same quarter last year. Operating income was $3.536 million compared to the $1.586 million for the same quarter year ago. Net cash provided by operating activities was $1.308 million compared to the $4.003 million for the same quarter year ago. Purchase of property and equipment was $1.140 million compared to the $0.919 million for the same quarter year ago. Adjusted EBITDA was $5.972 million compared to the $4.847 million for the same quarter year ago.
For the full year ending December 31, 2015, the company expected revenue in the range of $305 million to $310 million, representing growth of 5.3% to 7.0% year-over-year on a reported basis. The company expected Adjusted EBITDA in the range of $35 million to $37 million, representing growth of 7.9% to 14.1% year-over-year. Excluding the impact of foreign currency, Adjusted EBITDA is expected to increase 35.0% to 42.7% year-over-year. Non-GAAP EPS in the range of $0.62 to $0.66, representing growth of 9.1% to 16.1% year-over-year.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 18, 2015